BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  AstraZeneca, Daiichi Sankyo ADC Misses Endpoint in Phase III NSCLC Study

  AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel.

  May 28, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial

  NS Pharma, a subsidiary of Nippon Shinyaku, announced Monday that its Duchenne muscular dystrophy candidate Viltepso failed a late-stage confirmatory trial, showing no significant motor function improvements over placebo.

  May 28, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Novartis Eyes Rare Kidney Disease Approvals on Heels of Two Phase III Wins

  With back-to-back victories in IgA nephropathy and C3 glomerulopathy, Novartis on Saturday said it is planning to make regulatory submissions for the rare kidney diseases this year.

  May 28, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Novo Nordisk’s Once-Weekly Insulin Loses FDA Adcomm Vote for Type 1 Diabetes

  Flagging a risk of hypoglycemia, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Friday did not recommend the approval of Novo Nordisk’s once-weekly insulin icodec for type 1 diabetes.

  May 28, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics

  The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which won the FDA’s full approval in December 2023.

  May 28, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab

  Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the heels of J&J’s $850 million Proteologix bispecific antibody acquisition.

  May 28, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO

  AstraZeneca targets $80 billion in revenue by 2030, layoffs at Bayer, BMS and Pfizer continue to generate attention across the biopharma industry, Takeda takes a deep dive into the molecular glue space and conference season is in full swing.

  May 28, 2024

   · 

  1 min read

   · 

  Greg Slabodkin, Heather McKenzie, Tyler Patchen
• 

  Business

  How Realistic is AstraZeneca’s $80B Revenue Target by 2030?

  AstraZeneca last week set another ambitious goal, this time with plans to nearly double its total revenue by the end of the decade. However, it’s easier said than done, according to analysts.

  May 28, 2024

   · 

  4 min read

   · 

  Tyler Patchen
• 

  Career Advice

  Moving Up: 5 Tips for Transitioning From Co-Worker to Manager

  Transitioning from team member to manager has its challenges, including managing ex-peers. There are a few ways you can make the change easier.

  May 28, 2024

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Drug Development

  Measuring Muscle Loss in the ‘Wild West’ of Weight Loss Drugs

  The FDA currently does not recommend using changes in lean mass as an endpoint in clinical trials for weight loss drugs. Should it?

  May 28, 2024

   · 

  6 min read

   · 

  Gail Dutton